undamentalytics Newsletter

Altman Peter: insider trades

Chief executive at Biocardia, Inc. 15 open-market purchases and no sales not made under a pre-set plan, reported from March 22, 2018 to September 23, 2025.

Would copying Altman Peter’s purchases have beaten the S&P 500?

Too few purchases to judge. None of their purchases has 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. None of their purchases could be priced, so there is no copy portfolio. None of these trades can be measured yet: either the window after the report has not finished or the share price was under $5 when it was reported.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Altman Peter: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the trade 0 — — — — — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Biocardia, Inc. BCDA President and CEO150March 22, 2018September 23, 2025

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
September 23, 2025September 19, 2025 BCDA Purchase $60,000 not yetnot yetnot yet
July 2, 2025June 30, 2025 BCDA Purchase $50,120 not yetnot yetnot yet
April 25, 2025April 23, 2025 BCDA Purchase $50,130 not yetnot yetnot yet
February 15, 2024February 13, 2024 BCDA Purchase $49,730 not yetnot yetnot yet
May 13, 2022May 11, 2022 BCDA Purchase $18,586 not yetnot yetnot yet
April 18, 2022April 18, 2022 BCDA Purchase $18,765 not yetnot yetnot yet
November 18, 2021November 18, 2021 BCDA Purchase $11,000 not yetnot yetnot yet
August 18, 2021August 17, 2021 BCDA Purchase $10,290 not yetnot yetnot yet
December 1, 2020November 27, 2020 BCDA Purchase $10,074 not yetnot yetnot yet
March 16, 2020March 12, 2020 BCDA Purchase $10,710 not yetnot yetnot yet
January 3, 2020December 31, 2019 BCDA Purchase $14,680 not yetnot yetnot yet
October 4, 2019October 3, 2019 BCDA Purchase $19,798 not yetnot yetnot yet
May 2, 2019April 30, 2019 BCDA Purchase $11,890 not yetnot yetnot yet
November 16, 2018November 14, 2018 BCDA Purchase $14,971 not yetnot yetnot yet
March 22, 2018March 20, 2018 BCDA Purchase $10,150 not yetnot yetnot yet

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Altman Peter traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.